Epileptic encephalopathies are a heterogeneous group of severe childhood neurologic disorders characterized by epileptic activity accompanied by progressive cognitive, behavioral, and sensory impairments.^[@R1]^ In this study, we conduct functional analysis on 3 de novo missense mutations in *DNM1* that have been implicated in 2 epileptic encephalopathies: Lennox-Gastaut syndrome (LGS) and infantile spasms.

Dynamin-1 is a 100-kDa mechanochemical GTPase that is required during receptor-mediated endocytosis and synaptic vesicle recycling.^[@R2],[@R3]^ *DNM1*, expressed predominantly in neurons, localizes to the presynaptic terminal and mediates the uptake of synaptic vesicles.^[@R4][@R5][@R7]^ Its expression is upregulated during postnatal development, accompanying synaptogenesis.^[@R4],[@R7],[@R8]^

DNM1 is organized into 5 domains: a G domain that binds and hydrolyzes GTP, a middle domain that is involved in oligomerization, a GTPase effector domain, a pleckstrin homology domain, and a proline-rich domain.^[@R9][@R10][@R12]^ During receptor-mediated endocytosis, dynamin molecules assemble into tetramers that hydrolyze GTP.^[@R12],[@R13]^ Upon GTP hydrolysis, DNM1 undergoes a conformational change that allows it to pinch vesicles from the membrane.^[@R14]^

A spontaneous mouse mutation in the middle domain of *Dnm1* (*Dnm1*^Ftfl^) causes seizures and hearing defects.^[@R8]^ The missense mutation affects dynamin oligomerization and decreases endocytosis activity. Patch-clamp recordings demonstrate defects in GABAergic transmission in response to prolonged electrical stimulation.^[@R8]^

In this study, we assess the effects of 3 de novo mutations in *DNM1* using cellular assays and in vivo ultrastrucutral studies in mice*.* Collectively, this work provides a possible mechanistic link between synaptic vesicle trafficking dysfunction and epilepsy.

METHODS {#s1}
=======

Constructs. {#s1-1}
-----------

Wild-type (WT) *DNM1* cDNA was cloned into the pCMV-AC-GFP (OriGene, Rockville, MD) and pCMV-AC-RFP (OriGene) vectors in frame. Mutagenesis was performed on green fluorescent protein (GFP)-tagged DNM1 by site-directed mutagenesis using the NEB Q5 site-directed mutagenesis kit to create the c.529G\>C (A177P), c.618G\>C (K206N), and c.1076G\>C (G359A) mutations according to the manufacturer\'s protocol. Plasmid sequences were verified by Sanger sequencing.

Transferrin assay. {#s1-2}
------------------

COS-7 or HeLa cells were transfected on Mattek glass bottom plates with the DNM1 constructs using Lipofectamine LTX and PLUS reagent (Life Technologies, Grand Island, NY) according to the manufacturer\'s protocol. Twenty-four hours after transfection, the assay was performed with AlexaFluor-594--conjugated transferrin (Life Technologies), as previously described.^[@R8]^ Cells were mounted in VectaShield with 4\',6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA) and imaged with a Zeiss Axio Observer with a 63×, 1.4 oil immersion objective. Exposure times were adjusted for the GFP channel to better illustrate localization patterns. The experiment was repeated 3 times with identical conditions.

High-content imaging. {#s1-3}
---------------------

HeLa cells were transfected on Poly-[d]{.smallcaps}-Lysine--coated 24-well plates. The transferrin assay was performed as described. Using a Thermo Scientific Arrayscan VTI, cells were filtered for positive DAPI and GFP expression. To quantify transferrin uptake, AlexaFluor-594 (conjugated transferrin fluorophore) intensity was measured for each positively transfected cell. An average of 5,100 cells were analyzed per well. Spot identification was used to quantify the number of puncta per cell. Standardized evaluation was performed by applying the same parameters to each experimental condition. Downstream quantitative analysis was blinded.

Colocalization. {#s1-4}
---------------

HeLa cells were cotransfected with red fluorescent protein (RFP)-tagged WT *DNM1* and each of the GFP-tagged mutants on a 12-well Mattek glass bottom plate using Lipofectamine LTX with PLUS (Life Technologies). Twenty-four hours after transfection, cells were washed 3 times with ice-cold phosphate-buffered saline and fixed in 4% paraformaldehyde for 10 minutes at room temperature. Cells were mounted in VectaShield with DAPI (Vector Laboratories) and imaged with a Zeiss Axio Observer with a 63×, 1.4 oil immersion objective.

Western blot. {#s1-5}
-------------

### Monomer expression assay. {#s1-5-1}

HeLa cells were transfected with the DNM1 constructs. Twenty-four hours after transfection, cells were lysed in 200 μL of radioimmunoprecipitation assay (RIPA) buffer. The lysates were loaded on a 4%--12% NuPAGE Bis-Tris gel and transferred to a PVDF membrane. The blots were blocked in 1% casein solution and then probed with an anti-tGFP antibody (OriGene) at a 1:2,000 dilution overnight at 4°C. The membranes were washed 3 times with 0.1% Tris-buffered saline (TBS)-Tween. They were then probed with IRDye 800CW anti-mouse antibody (LI-COR, Lincoln, NE) at a 1:2,000 dilution for 1 hour at room temperature. The membranes were again washed 3 times in 0.1% TBS-Tween and imaged. Densitometry was performed using ImageJ, and downstream quantification was performed using a blinded analysis.

### Cross-linking assay. {#s1-5-2}

HeLa cells were transfected as described above. Twenty-four hours after transfection, the cells were lysed in RIPA buffer and treated with 20 mM 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) for 45 minutes at 4°C. The Western blot was then performed as described for the monomer expression assay.

HeLa cell electron microscopy. {#s1-6}
------------------------------

HeLa cells were transfected with WT and mutant constructs using Lipofectamine LTX on a Millipore 4-chamber Millicell EZ slide according to the manufacturer\'s protocol (Life Technologies). Twenty-four hours after transfection, the cells were fixed in 4% glutaraldehyde in borate buffer, dehydrated, and embedded. Images were acquired on a Phillips CM12.

Mice. {#s1-7}
-----

C57BL/6J-Dnm1Ftfl mice arose at The Jackson Laboratory (Bar Harbor, ME) as a spontaneous mutation on the C57BL/6J inbred strain in 2000.^[@R8]^ All mice were housed and procedures performed with approval of Institutional Animal Care and Use Committee. All mice were obtained from The Jackson Laboratory, maintained in a room with a 14-hour light on/10-hour light off cycle, and given free access to LabChow meal and water.

Brain section electron microscopy. {#s1-8}
----------------------------------

For electron microscopy (EM), littermate C57BL/6J-Dnm1Ftfl/Ftfl and C57BL/6J-Dnm1+/+ mice (aged 2 weeks) were perfused transcardially with 2% paraformaldehyde-2% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4), and the brains were removed and postfixed overnight at 4°C. Samples were postfixed with 1% OsO~4~ in 0.1 M cacodylate buffer, dehydrated, and embedded. Grids were scanned on a JEOL 1230 Transmission Electron Microscope, and measurements were performed with ImageJ software. For synaptic vesicle diameter and number analysis, a minimum of 710 vesicles from each sample was measured. Synaptic vesicle number was normalized to the area of each synapse measured.

RESULTS {#s2}
=======

We examined a total of 3 de novo missense mutations in *DNM1* (NM_001005336.1) c.529G\>C (p.(Ala177Pro)) (patient 1), c.618G\>C (p.(Lys206Asn)) (patient 2), and c.1076G\>C (p.(Gly359Ala)) (patient 3). Two amino acid substitutions (A177P and K206N) appear in the G domain of *DNM1* and the third substitution (G359A) occurs in the middle domain ([figure 1A](#F1){ref-type="fig"}). Clinical features of the probands harboring variants in *DNM1* have been reported.^[@R15]^ All 3 patients had infantile spasms with onset between 2 and 7 months, later evolving into LGS. In addition, each patient presented with severe intellectual disability, pronounced hypotonia, and absence of speech. Patients 1 and 2 are therapy resistant, while patient 3 has been seizure free since beginning a ketogenic diet at age 3. In addition, patient 1 was diagnosed with autism spectrum disorder.

![DNM1 mutations and structure\
(A) Structure-based domain architecture of human DNM1. The A177P and K206N mutations occur in the G domain and the G359A mutation occurs in the middle domain. The location of the mouse *Dnm1*^Ftfl^ (A408T) mutation is indicated above the middle domain. (B) Positions of the amino acid substitutions in the DNM1 crystal structure, shown as a ribbon-type representation.](NNG-D-15-00004FF1){#F1}

Available in silico algorithms predict that all 3 missense mutations are likely highly damaging to the encoded DNM1 protein (PolyPhen-2 score = 1.00; SIFT score = 0).^[@R16],[@R17]^ In addition, *DNM1* is among the 20% of genes that are the most intolerant of functional genetic variation in the human population.^[@R18]^ The A177P mutation occurs at the C-terminus of β-pleated sheet β4^G^. The K206N mutation substitutes a charged amide residue for a neutral residue at the C-terminus of β-pleated sheet β5^G^. The G359A mutation occurs at the N-terminus of α helix α1M^s^ ([figure 1B](#F1){ref-type="fig"}). The GERP++ scores at these 3 missense positions (5.42, 4.41, and 5.88, respectively) are much higher than the average *DNM1* GERP++ score of 3.77, indicating that these sites are highly conserved relative to the overall conservation of the gene.

Dynamin plays a crucial role in the catalysis of clathrin-mediated endocytosis. To determine whether these mutations affect endocytosis, we transfected COS-7 cells with GFP-tagged *DNM1* constructs and measured effects on uptake of fluorescently labeled transferrin. Cells containing WT-transfected *DNM1* showed a perinuclear accumulation of the fluorescently labeled transferrin ([figure 2A](#F2){ref-type="fig"}). However, overexpression of the G-domain mutants, A177P and K206N, significantly inhibited transferrin uptake ([figure 2, B and C](#F2){ref-type="fig"}). The middle-domain mutation, G359A, showed some transferrin uptake in occasional cells but was largely inhibited ([figure 2D](#F2){ref-type="fig"}). In addition to their effects on endocytosis, the mutant DNM1 proteins exhibited different patterns of localization. WT DNM1 formed distinct, round puncta ([figure 2A](#F2){ref-type="fig"}), while the A177P mutant had a diffuse cytosolic distribution accompanied by puncta ([figure 2B](#F2){ref-type="fig"}). The K206N mutant exhibited abnormally large protein aggregates with a nonuniform distribution throughout the cell ([figure 2C](#F2){ref-type="fig"}). Finally, the G359A mutant dynamin lacked puncta and exhibited a reticular distribution throughout the cell ([figure 2D](#F2){ref-type="fig"}).

![DNM1 mutations inhibit transferrin uptake\
Inhibition of transferrin internalization in mammalian cell lines. COS-7 cells were transfected with green fluorescent protein (GFP)-tagged *DNM1* constructs and then treated with fluorescently labeled transferrin. Scale bar, 20 μm. (A) Cells expressing wild type (WT) *DNM1* exhibit transferrin uptake with a perinuclear accumulation. WT DNM1 forms round puncta that are evenly dispersed throughout the perimeter of the cell. (B) The A177P mutant inhibits transferrin uptake. *DNM1* shows some diffuse GFP signal throughout the cytosol accompanied by puncta. (C) The K206N mutant also inhibits transferrin uptake and shows abnormal aggregation of DNM1. (D) The G359A mutant shows some transferrin uptake in certain cells. There is a distinct lack of puncta, and DNM1 shows a reticular GFP signal throughout the cytosol.](NNG-D-15-00004FF2){#F2}

To quantify differences in endocytosis levels and localization of *DNM1*, we performed high-content imaging analyses on transfected HeLa cells. First, intensity of the transferrin fluorophore was measured in positively transfected cells. Compared to cells transfected with the WT *DNM1* construct, overexpression of each mutant protein conferred nearly a 60% reduction in transferrin uptake ([figure 3A](#F3){ref-type="fig"}). Spot identification analysis was used to quantify differences in puncta per cell and revealed a 50% reduction in the number of puncta in the G359A mutant ([figure 3B](#F3){ref-type="fig"}).

![Quantification of transferrin uptake and cellular localization patterns\
(A) High-content imaging analysis of transferrin fluorophore intensity in positively transfected HeLa cells. All 3 mutations confer nearly a 60% reduction in transferrin uptake compared to wild type (WT). Error bars represent SD between 5 replicate wells. *p* \< 0.05 by Student *t* test. (B) High-content imaging spot identification revealed a 50% reduction in the number of puncta in cells expressing the G359A mutation. Error bars represent SD among 5 replicate wells. \**p* \< 0.05 by Student *t* test.](NNG-D-15-00004FF3){#F3}

Because DNM1 is the predominant dynamin in neurons,^[@R19]^ we were interested to see whether the mutant forms of the protein could colocalize with WT DNM1. To test this hypothesis, RFP-tagged WT *DNM1* was cotransfected with each of the GFP-tagged mutants. Each mutant protein significantly colocalized with WT DNM1, suggesting likely interaction between the WT and mutant proteins (figure e-1 at [Neurology.org/ng](10.1212/01.NXG.0000464295.65736.da)). Additionally, in contrast to the aberrant localization patterns when transfected alone, all 3 mutant proteins formed puncta in the presence of WT DNM1.

Because these mutations were predicted to be highly damaging to functional DNM1, we performed a Western blot on transfected HeLa cells to assay possible differences in expression levels ([figure 4A](#F4){ref-type="fig"}). Average normalized WT and mutant DNM1 levels were determined and are shown in [figure 4B](#F4){ref-type="fig"}. The K206N mutant protein showed a 75% decrease in steady-state levels compared to WT. It is interesting that the G359A transfected cells showed nearly a 2-fold increase in expression.

![DNM1 mutations affect protein levels and self-dimerization\
(A) HeLa cells were transfected with green fluorescent protein (GFP)-tagged mutant constructs. The blots were probed with anti-GFP antibodies. A representative blot is shown. (B) Quantification of protein expression levels from 3 independent Western blot experiments is shown. Actin levels were used for normalization and error bars indicate SD values. \**p* \< 0.05 by Student *t* test. (C) HeLa cell lysates from cells transfected with GFP-tagged mutant constructs were treated with 20 mM 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) cross-linking agent and analyzed by Western blot. The monomeric and dimeric forms are indicated. WT = wild type.](NNG-D-15-00004FF4){#F4}

We next conducted a cross-linking assay to test whether the mutations disrupt DNM1 protein dimerization. We suspected that mutant G359A would disrupt dimerization, as the middle domain is involved in dynamin self-assembly, as shown previously for the mouse *Dnm1*^Ftfl^ mutation.^[@R8]^ Forty-eight hours after transfecting HeLa cells with mutant constructs, cell lysates were treated with 20 mM EDC, a zero-length cross-linking agent, and analyzed by Western blot with anti-GFP antibody. The relative levels of monomer and dimer are shown in [figure 4C](#F4){ref-type="fig"}. The G-domain mutants showed similar dimerization patterns to WT, but the G359A middle-domain mutant was associated with nearly a 50% decrease in dimerization, consistent with the *Dnm1*^Ftfl^ result.

During endocytosis, DNM1 pinches forming vesicles from the plasma membrane. We conducted EM on transfected HeLa cells to determine effects of the mutants on vesicle scission. In cells transfected with the A177P construct, we observed extremely large abnormally shaped vesicles and smaller vesicles that clustered at the edge of the plasma membrane ([figure 5A](#F5){ref-type="fig"}). This finding supports our hypothesis that G-domain DNM1 mutations significantly affect vesicle formation. Previously reported dominant-negative G-domain DNM1 mutants exhibited deep clathrin-coated invaginations in the membrane by EM,^[@R14]^ but while we observed this phenotype in the G359A construct by immunofluorescence, we were not able to detect it by EM for these mutations. In contrast, in cells transfected with the G359A mutant construct, there were no obvious vesicle abnormalities ([figure 5A](#F5){ref-type="fig"}).

![Electron microscopy of transfected HeLa cells and *Dnm1*^Ftfl^ neurons\
(A) Electron microscopy (EM) of HeLa cells transfected with wild type (WT) and mutant DNM1 constructs. There are larger and abnormal vesicles in the A177P mutant. Cells transfected with the G359A show no obvious vesicle defects. Scale bars, 1 μm. (B) EM of WT mouse brain sections. (C) EM of *Dnm1*^Ftfl^ mouse neurons reveals increased vesicle size. (D) A box plot depicting the number of vesicles in both WT and *Dnm1*^Ftfl^ neurons. Outliers are excluded from the plot. Significance was determined by the Mann-Whitney-Wilcoxon test (\*\**p* \< 0.005, \*\*\**p* \< 0.0005). (E) A box plot depicting the size of vesicles in both WT and *Dnm1*^Ftfl^ neurons. There were significantly larger vesicles in both hippocampal and cortical neurons. Outliers are excluded from the plot. Significance was determined by the Mann-Whitney-Wilcoxon test.](NNG-D-15-00004FF5){#F5}

Because the previously reported *Dnm1*^Ftfl^ mutation ([figure 1A](#F1){ref-type="fig"}) results in an early-onset seizure disorder in the mouse, decreases endocytosis activity in heterologous expression assays, and decreases oligomerization of DNM1,^[@R8]^ we reasoned that this mutation acts as a good model of the 3 human mutations. To understand the effects of DNM1 mutations on vesicle trafficking in vivo, we conducted EM on brain sections of the *Dnm1*^Ftfl^ mouse. Overall, we observed a significant general decrease in vesicle number and an increase in vesicle size in synapses from both hippocampal and cortical regions when compared with WT ([figure 5, B--D](#F5){ref-type="fig"}). Together, these findings suggest a stall in the overall fission activity of mutant DNM1, resulting in larger and fewer vesicles indicative of defects in endocytosis.

DISCUSSION {#s3}
==========

In this study, we analyzed the functional consequences of 3 de novo *DNM1* missense mutations that were identified among patients with LGS, a severe epileptic encephalopathy. When expressed alone in COS-7 and HeLa cells, all 3 mutant constructs significantly inhibited endocytosis. Cells that overexpress WT *DNM1* do not show an increase in overall transferrin uptake compared to cells transfected with a control GFP construct. Thus, the significant decrease in transferrin uptake suggests a dominant-negative effect of all 3 mutations, consistent with several other reported *DNM1* mutations.^[@R14]^ Furthermore, mammalian genomes contain a total of 3 dynamin genes: *DNM1, DNM2*, and *DNM3*.^[@R20]^ *DNM2* is expressed ubiquitously,^[@R21]^ while *DNM3* is expressed in the brain and the testes.^[@R4]^ Given the ubiquitous expression of *DNM2*, the profound inhibitory effect on endocytosis suggests that the mutant DNM1 proteins bind to endogenous DNM2, thus interrupting DNM2 function and causing an accumulation of endocytotic intermediates.^[@R4],[@R8]^

Both G-domain mutant proteins, A177P and K206N, showed different localization patterns from WT when expressed alone. EM revealed dramatic vesicle abnormalities, and our Western blot results indicate that neither mutation affects dimerization, but there is a significant decrease in steady-state levels of the K206N mutant, possibly suggesting decreased stability of this protein. Our co-transfection studies indicate that both mutant proteins colocalize---and presumably dimerize---with WT DNM1. We hypothesize that these mutations decrease GTP hydrolysis in a fashion similar to that reported for other dominant-negative G-domain mutants.^[@R2],[@R14],[@R22]^ Because GTP hydrolysis is necessary for vesicle scission,^[@R14]^ disruptions to this process likely lead to the observed decreased endocytosis activity.

The middle-domain mutation, G359A, also affected DNM1 localization. It is interesting that this mutant protein exhibited a reticular, or tube-like, distribution correlating with the transferrin signal. This is highly similar to what is observed when the Dnm1-Ftfl protein is overexpressed in COS-7 cells.^[@R8]^ Other studies of dominant-negative *DNM1-*expressing cells have reported reticular localization of some mutants, proposing that mutant dynamin can assemble on and tubulate the membrane but cannot function to fission the membrane, thus resulting in a longer lifetime on the membrane than WT dynamin.^[@R14]^

The middle-domain mutation interfered with DNM1 dimerization and showed nearly a 2-fold increase in monomer expression compared to WT. Since each of these proteins is expressed from cDNA constructs with constitutive cytomegalovirus promoters, these observations suggest different stabilities of the WT and mutant proteins. However, it is unclear why the monomeric form is more stable. Membrane invagination and fission are mediated by 2 separate dynamin mechanisms that require both assembly-independent and assembly-dependent GTPase activity.^[@R23],[@R24]^ Thus, we hypothesize that an increase in the monomeric form of this mutant protein may allow it to bind to and sequester certain interacting vesicle trafficking partners to achieve its dominant-negative effect. It is interesting that cells expressing the G359A mutant protein did not show the same vesicle defects as cells transfected with the G-domain mutant constructs in EM. As previously hypothesized for the mouse fitful mutation, which also occurs in the middle domain, we believe that the G359A mutant would not participate in assembly-stimulated activity required for vesicle scission but would retain the assembly-independent activity required for membrane invagination.^[@R8]^

The G359A and *Dnm1*^Ftfl^ constructs produce the same cellular phenotype when expressed in COS-7 cells: decreased transferrin endocytosis, a reticular *DNM1* distribution, and decreased dimerization. Thus, the *Dnm1*^Ftfl^ mutation is a very good model for this mutation. Our EM data from *Dnm1*^Ftfl^ neurons reveal an overall increase in vesicle size coupled with a decrease in vesicle number. Because dynamin-mediated scission is the rate-limiting step of endocytosis,^[@R25]^ these results suggest a stall in the endocytosis process due to decreased dynamin-mediated membrane fission. Together, these data illustrate that dominant-negative *DNM1* mutations are also likely to disrupt vesicle trafficking in vivo.

Although they may achieve a dominant-negative interaction through different mechanisms, each mutant protein causes endocytosis defects, as suggested by our transferrin assay. One possible consequence is that decreased endocytosis activity results in a depleted pool of synaptic vesicles, as supported by EM of fitful neurons. It has been previously shown that inhibitory neurons are more sensitive to the lack of *DNM1,* presumably due to their tonic activity.^[@R26]^ Thus, a lack of synaptic vesicles in inhibitory neurons could cause decreased GABA transmission, leading to network-level hyperactivity and an epileptic phenotype. Alternatively, these mutations may affect neurite formation, as recent evidence illustrates that inhibiting dynamin-dependent endocytosis disrupts neurite outgrowth.^[@R27]^ Additional neuronal-based studies are required to fully elucidate the downstream effects of inhibited neuronal endocytosis.

Our study adds to the increasing evidence that dysfunctional synaptic vesicle cycling is a mechanism for neurologic disorders. Mutations in other vesicle trafficking genes, such as *STXBP1*, *SYN1*, and *LRRK2,* have been implicated in autism spectrum disorder, epileptic encephalopathies, and Parkinson disease.^[@R27][@R28][@R29]^ Together, these studies support the emerging paradigm in neurology that disruptions in the same pathway can increase risk for a broad range of neuropsychiatric disorders.^[@R30]^

Finally, our results emphasize that functional analysis driven by genomic data can play an important role in discovering novel disease mechanisms. A wide spectrum of proteins, including channel proteins, protein modifiers, RNA binding proteins, and others, have been implicated in LGS alone.^[@R31]^ Thus, due to their genetic heterogeneity, treatment considerations for epileptic encephalopathies will eventually be guided by the underlying pathogenic mechanism in any given patient. Further understanding of the relation between synaptic vesicle dysfunction and epilepsy will facilitate the discovery of treatment opportunities.

Supplementary Material
======================

###### Data Supplement

Supplemental data at [Neurology.org/ng](http://Neurology.org/ng)
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